X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Aramchol meglumine is a first-in-class, novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, liver targeted SCD1 modulato which is being developed for the treatment of primary sclerosing cholangitis.
Lead Product(s): Aramchol Meglumine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Under the partnership, OnKai will apply its AI, models for enrollment and execution of clinical trials in underserved communities, starting with Galmed's innovative Primary Sclerosing Cholangitis clinical program evaluating Aramchol (arachidyl amido cholanoic acid).
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: OnKai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 10, 2023
Details:
Aramchol meglumine is a first-in-class, novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, liver targeted SCD1 modulato which is being developed for the treatment of primary sclerosing cholangitis.
Lead Product(s): Aramchol Meglumine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Virginia Commonwealth University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Arachidyl amido cholanoic acid is a first-in-class, novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (nonalcoholic steatohepatitis) and fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Aramchol (Arachidyl amido cholanoic acid) is a first-in-class, novel synthetic small molecule, a conjugate, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (nonalcoholic steatohepatitis) and fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Recent data reinforce the anti-fibrotic activity of Aramchol (arachidyl amido cholanoic acid) previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement using NASH CRN, paired ranked reading and Artificial Intelligence (AI) quantitative digital analysis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
New Patents granted by USPTO for low dose composition Aramchol (Arachidyl Amido Cholanoic Acid), including Meglumine Salt currently undergoing phase 3 study for the treatment of fibrosis and modulating gut microbiota.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
Data from first 20 patients from the ARMOR study Open Label Part showing that treatment with Aramchol 300mg BID resulted in clinically significant greater histological improvement in 12 out of 20 (60%) of patients.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis.
Lead Product(s): Aramchol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
